TG Therapeutics Inc (NASDAQ:TGTX) on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.

The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million.

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2025 is off to a strong start, and I’m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI’s $119.7 million in U.S. net sales, demonstrates the growing confidence in our treatment and the increasing adoption by healthcare providers. This momentum, combined with the positive feedback we’re hearing from both patients and clinicians, reinforces our belief that we can achieve our long-term goal of BRIUMVI becoming the number one prescribed anti-CD20 treatment based on dynamic market share.”

“In addition to our ongoing BRIUMVI commercialization efforts, we are continuing to invest in innovation, including simplifying the BRIUMVI treatment regimen, advancing subcutaneous BRIUMVI, and developing azer-cel for progressive MS,” Weiss added.

Briumvi sales reached $119.7 million.

Also Read: Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

The company said it presented five-year data from the open-label extension study of the ULTIMATE I & II Phase 3 trials evaluating Briumvi in adult patients with relapsing forms of multiple sclerosis (RMS).

• The data demonstrated that 92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile that remained consistent, with no new safety signals emerging over 5 years of continuous treatment and no observed cases of progressive multifocal leukoencephalopathy (PML) to date.

Also Read: Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

The company also presented data from the ENHANCE Phase 3b trial evaluating alternative dosing strategies for Briumvi in patients with RMS, which demonstrated that:

• A single 600 mg Briumvi infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status.
• Rapid 30-minute Briumvi infusions were well tolerated in patients with RMS.

Guidance: TG Therapeutics raised Briumvi’s U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance.

• The company raised the total global revenue target to $575 million from prior guidance of $540 million.

Briumvi’s U.S. net product revenue is expected to be $135 million in the second quarter of 2025.

Price Action: TGTX stock was down 13.2% at $37.68 on Monday.

Read Next:

• Berkshire Hathaway Stock Falls Following Buffett’s Retirement As CEO

Photo: Shutterstock